Overview

A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

Status:
Active, not recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
Current clinical practices has shown promising prospects of the therapy strategy of interferon combined with nucleos(t)ides in patients with chronic hepatitis B, but the safety and efficacy has not been fully studied. This study is aimed to exploit the safety and efficacy of the study drug, Peginterferon alfa-2b injection, with nucleos(t)ide (NAs), tenofovir disoproxil fumarate tablets (TDF), in the patients with hepatitis B, who has previously treated with nucleos(t)ides and who are treatment naïve.
Phase:
Phase 3
Details
Lead Sponsor:
Xiamen Amoytop Biotech Co., Ltd.
Collaborator:
Peking University First Hospital
Treatments:
Interferon-alpha
Peginterferon alfa-2b